Metrikler
Yayın
18
Açık Erişim
5
BM Sürdürülebilir Kalkınma Amaçları
Makaleler
Tümü (18)
SCI-E, SSCI, AHCI (15)
SCI-E, SSCI, AHCI, ESCI (16)
Scopus (18)
TRDizin (3)
2025
20251. Artificial Intelligence (ChatGPT-4o) in Adjuvant Treatment Decision-Making for Stage II Colon Cancer: A Comparative Analysis with Clinician Recommendations and NCCN/ESMO Guidelines
KUŞ F., Chalabiyev E., YILDIRIM H. Ç., Koc Kus I., ŞİRVAN F., DİZDAR Ö., et al.
UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI
, cilt.35, sa.1, ss.68-74, 2025 (SCI-Expanded, Scopus, TRDizin)
2025
20252. Comparative Analysis of Prognostic Potential of Pretreatment Blood-Based Biomarkers in Metastatic Bladder Cancer: Modified Glasgow Prognostic Score
KUŞ F., GÜVEN D. C., YILDIRIM H. Ç., Chalabiyev E., Koc I., Tatar O. D., et al.
JOURNAL OF CLINICAL MEDICINE
, sa.6, 2025 (SCI-Expanded, Scopus)
2025
20253. Efficacy and Clinical Outcomes of Crizotinib in Patients with ROS1-Rearranged NSCLC: A Multicenter Study
Topal A., Akdag G., Yildirim S., Kinikoglu O., Isik D., Yildirim G., et al.
MEDICINA-LITHUANIA
, sa.3, 2025 (SCI-Expanded, Scopus)
2025
20254. Dynamine 3 as a diagnostic and prognostic biomarker in pancreatic cancer: Implications for early detection and targeted therapy
Yay F., Yildirim H. c., KUŞ F., YALÇIN Ş.
BIOMARKERS
, sa.2, ss.147-166, 2025 (SCI-Expanded, Scopus)
2025
20255. Regorafenib Treatment for Recurrent Glioblastoma Beyond Bevacizumab-Based Therapy: A Large, Multicenter, Real-Life Study
TÜNBEKİCİ S., YÜKSEL H. Ç., ACAR C., Sahin G., Orman S., Majidova N., et al.
CANCERS
, cilt.17, sa.1, 2025 (SCI-Expanded, Scopus)
2024
20246. Association Between Baseline and Changes in Early Neutrophil-to-Lymphocyte Ratio on Survival in Patients with Metastatic Bladder Carcinoma Treated with Immunotherapy
Degerli E., Arslan C., Selcukbiricik F., Olmez O. F., Erdem D., Hamdard J., et al.
MEDICINA-LITHUANIA
, cilt.60, sa.12, 2024 (SCI-Expanded, Scopus)
2024
20247. The impact of human epidermal growth factor receptor-2 (low) status on the efficacy of first line cyclin-dependent kinase 4/6 inhibitors in advanced breast cancer
YILDIRIM H. Ç., Buyukkor M., KAVGACI G., ŞAHİN ÇELİK B., BİR YÜCEL K., DURSUN B., et al.
MEDICINE
, cilt.103, sa.30, 2024 (SCI-Expanded, Scopus)
2024
20248. The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study
Yıldırım H. Ç., KUTLU Y., Mutlu E., Aykan M. B., Korkmaz M., Yalçın S., et al.
International Journal of Clinical Oncology
, cilt.29, sa.3, ss.258-265, 2024 (SCI-Expanded, Scopus)
2024
20249. Sirolimus experience in adult patients with vascular malformations
AKYILDIZ A., Ismayilov R., GÜVEN D. C., YILDIRIM H. Ç., Tatar O. D., KUŞ F., et al.
Vascular
, 2024 (SCI-Expanded, Scopus)
2024
202410. The Use of Herbal Medicine and Dietary Supplements in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Multicenter Cross-Sectional Study
KUŞ F., GÜVEN D. C., YILDIRIM H. Ç., Akagunduz B., Karakaya S., SÜTCÜOĞLU O., et al.
INTEGRATIVE CANCER THERAPIES
, cilt.23, 2024 (SCI-Expanded, Scopus)
2023
202311. Mean Platelet Volume to Lymphocyte Ratio: A New Biomarker Predicting Response in Patients with Solid Tumors Treated with Nivolumab
YILDIRIM H. Ç., KUŞ F., GÜVEN D. C., Karaca E., KAYGUSUZ Y., DİZDAR Ö., et al.
Journal of Immunotherapy and Precision Oncology
, cilt.6, sa.4, ss.170-176, 2023 (Scopus)
2023
202312. Do statins enhance the antitumor effect of trastuzumab emtansine (T-DM1)?: Real-life cohort
AKYILDIZ A., GÜVEN D. C., YILDIRIM H. Ç., Ismayilov R., YILMAZ F., Tatar O. D., et al.
Medicine (United States)
, cilt.102, sa.18, 2023 (SCI-Expanded, Scopus)
2023
202313. KELIM score predicts outcome in patients with platinum-resistant/refractory recurrent ovarian cancer
KUŞ F., Guven D. C., YILDIRIM H. Ç., Chalabiyev E., AKYILDIZ A., Tatar O. D., et al.
Biomarkers in Medicine
, cilt.17, sa.7, ss.379-389, 2023 (SCI-Expanded, Scopus)
2023
202314. Knowledge and Protective Behaviors of Teachers on Skin Cancer: A Cross-Sectional Survey Study from Turkey
Kus C., Kus M. M., Keten H. S., Ucer H., Guvenc N., KUŞ F., et al.
Children
, cilt.10, sa.2, 2023 (SCI-Expanded, Scopus)
2023
202315. Prognostic Value of Androgen Receptor Expression in Premenopausal Women with Estrogen Receptor-Positive Breast Cancer
YILDIRIM H. Ç., ÜNER M., Yildiran Özmen T., Chalabiyev E., GÜVEN D. C., KUŞ F., et al.
Journal of Oncological Science
, cilt.9, sa.1, ss.33-37, 2023 (Scopus, TRDizin)
2023
202316. Optimal adjuvant treatment strategies for TNBC patients with residual disease after neoadjuvant treatment
Guven D. C., YILDIRIM H. Ç., KUŞ F., Erul E., KERTMEN N., DİZDAR Ö., et al.
Expert Review of Anticancer Therapy
, cilt.23, sa.10, ss.1049-1059, 2023 (SCI-Expanded, Scopus)
2023
202317. Emerging treatment strategies in hepatobiliary cancer
GÜVEN D. C., YILDIRIM H. Ç., Chalabiyev E., KUŞ F., YILMAZ F., YAŞAR S., et al.
Expert Review of Anticancer Therapy
, cilt.23, sa.3, ss.243-256, 2023 (SCI-Expanded, Scopus)
2022
202218. Prognostic Factors Associated with Locally Advanced Gastric Cancer in Patients Treated with Adjuvant Chemotherapy
YILDIRIM H. Ç., Güven D. C., Chalabiyev E., Taban H., YILMAZ F., YAŞAR S., et al.
Journal of Oncological Science
, cilt.8, sa.3, ss.143-147, 2022 (Scopus, TRDizin)